C4X Discovery Holdings plc (AIM:C4XD), a healthcare services company based in United Kingdom, saw a significant share price rise of over 20% in the past couple of months on the AIM. Less-covered, ...

22 September 2025 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company, today announces the selection of a potential best-in-class pre-clinical candidate from its oral α4β7 ...

Indivior has paid 15.95 million pounds sterling ($20.4 million) to C4X Discovery for the full rights to the British biotech’s orexin-1 receptor antagonist being developed for substance use disorder.

22 July 2024 - C4X Discovery Limited (“C4XD”), a pioneering drug discovery company, today provides an update on the business following its delisting from AIM earlier in the year. Clive Dix, Executive ...

Manchester and London, UK, 12 June, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced the appointment of Piers Morgan as Chief Executive Officer with ...

April 12 (Reuters) - Drug developer C4X Discovery C4XD.L said on Monday it has signed an exclusive licensing deal worth up to 414 million euros ($492.12 million) with French drugmaker Sanofi SASY.PA ...

Gene-editing specialists Horizon Discovery is to work with C4X Discovery to exploit CRISPR-Cas9 and other novel technologies to develop new oncology candidates. The two UK-based companies are among a ...

LONDON (Reuters) -Drug developer C4X Discovery said on Monday it had signed an exclusive licensing deal worth up to 414 million euros ($492.12 million) with French drugmaker Sanofi to develop an oral ...

Shares in C4X Discovery Holdings PLC rose Monday after the company said it has signed a licensing agreement with French pharmaceutical major Sanofi SA to develop a preclinical program as an oral ...